3D MEDICINES (01244): 3D Medicines Hong Kong and Mega Link entered into a renewal agreement for the short-term note agreement

3D MEDICINES (01244) announced that on August 14, 2023, the company's wholly-owned subsidiary 3D Medicines (Hong Kong) Co., Limited (3D Medicines Hong Kong) entered into a short-term note agreement (the Initial Agreement) with Mega Link International Limited (Mega Link), an independent third-party company, with a principal amount of HK$50 million, bearing interest at a rate of 6% per annum for the period from August 14, 2023 to August 14, 2025, and at a rate of 7.5% per annum for the period from August 15, 2025 to August 14, 2026. The note completed its first renewal on August 15, 2024, and its second renewal on August 15, 2025, with the principal amount remaining unchanged except for interest rate adjustments as agreed. In order to optimize the Group's capital allocation and continuously obtain stable investment returns through prudent financial management, 3D Medicines Hong Kong and Mega Link entered into a supplemental agreement (the Renewal Agreement) in 2026 to renew the maturity date of the note. Following the renewal, the maturity date is August 14, 2028. The coupon rate is 9% per annum. Through this note extension, the Group is able to continuously obtain stable interest income and improve capital utilization efficiency, and the proceeds from the transaction will be used to supplement the Group's research and development investment and daily operating capital, which is in the overall interest of the company and its shareholders.